Pretransplant donor and recipient CTLA-4 mRNA and protein levels as a prognostic marker for aGvHD in allogeneic hematopoietic stem cell transplantation.
PBN-AR
Instytucja
Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda Polskiej Akademii Nauk
Informacje podstawowe
Główny język publikacji
EN
Czasopismo
Immunology letters
ISSN
0165-2478
EISSN
1879-0542
Wydawca
Amsterdam, Elsevier/North-Holland Biomedical Press
Rok publikacji
2015
Numer zeszytu
1
Strony od-do
52–59
Numer tomu
165
Identyfikator DOI
Liczba arkuszy
Słowa kluczowe
EN
Hematopoietic stem cell transplantation
Acute graft vs host disease
CTLA-4
Protein expression level
mRNA expression level
Open access
Tryb otwartego dostępu
Inne
Wersja tekstu w otwartym dostępie
Wersja opublikowana
Licencja otwartego dostępu
Inna
Czas opublikowania w otwartym dostępie
Razem z publikacją
Data udostępnienia w sposób otwarty
Streszczenia
Język
EN
Treść
Background Cytotoxic T lymphocyte antigen-4 (CTLA-4) is an inhibitory T cells’ receptor essential for maintaining T cell homeostasis and immunotolerance. The role of the co-stimulatory pathway in development of aGvHD has been studied mostly in animal models. To the best of our knowledge, there are no published data on the role of CTLA-4 in pathogenesis of aGvHD after hematopoietic stem cell transplantation (HSCT) in humans. Therefore the aim of our study was to determine the association of CTLA-4 mRNA and proteins level in HSCT donor–recipient pairs, prior to and after HSCT, with aGvHD risk. Methods Total CTLA-4 mRNA level in 51 donor–recipient pairs prior to and 56 days after HSCT was determined using real time PCR techniques, while membrane (m) and cytoplasmic (c) CTLA-4 expression in CD3+ cells were measured by flow cytometry in 40 donor–recipient pairs at the same time points. Results We found an association between the risk of aGvHD and high pre-transplant CTLA-4 mRNA expression level both in recipients and in donors, stronger in recipients (OR = 2.02, CI95% 1.39–3.01), and less pronounced in donors (OR = 1.57, CI95% 1.18–2.0). Moreover, we showed that proportion of CD3+ cells positive for mCTLA-4 in recipients prior to HSCT positively correlated with increased risk of aGvHD (OR = 1.175, CI95% 1.024–1.311, p = 0.018). Conclusion Our results indicate that both donor and recipient CTLA-4 mRNA as well as recipient membrane protein expression levels measured before transplantation may be considered as prognostic factors for aGvHD development.
Cechy publikacji
artykuł oryginalny
Inne
System-identifier
PX-56b48bca8106eb71826f8196
CrossrefMetadata from Crossref logo
Cytowania
Liczba prac cytujących tę pracę
Brak danych
Referencje
Liczba prac cytowanych przez tę pracę
Brak danych